Nyxoah (NASDAQ:NYXH) Shares Down 0.4% – Time to Sell?

Nyxoah SA (NASDAQ:NYXH)’s share price traded down 0.4% during trading on Monday . The stock traded as low as $4.71 and last traded at $4.73. 58,240 shares changed hands during mid-day trading, an increase of 18% from the average session volume of 49,361 shares. The stock had previously closed at $4.75.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on NYXH shares. Stifel Nicolaus reduced their price target on Nyxoah from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Nyxoah in a report on Monday, December 29th. Finally, Piper Sandler reissued an “overweight” rating and issued a $9.00 target price (down previously from $12.00) on shares of Nyxoah in a research report on Friday, November 14th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Nyxoah has an average rating of “Moderate Buy” and an average price target of $11.67.

Nyxoah Stock Down 0.4%

The stock has a 50 day moving average price of $4.81 and a 200 day moving average price of $5.51. The company has a quick ratio of 1.41, a current ratio of 1.70 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $161.10 million, a price-to-earnings ratio of -1.90 and a beta of 1.55.

Nyxoah (NASDAQ:NYXH) last announced its earnings results on Friday, November 14th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.13). The company had revenue of $2.31 million for the quarter, compared to analyst estimates of $1.95 million. Nyxoah had a negative return on equity of 101.99% and a negative net margin of 1,457.97%. As a group, analysts forecast that Nyxoah SA will post -1.91 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its stake in shares of Nyxoah by 72.4% in the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after purchasing an additional 3,303 shares during the last quarter. Raymond James Financial Inc. bought a new position in Nyxoah in the 2nd quarter valued at $70,000. Citadel Advisors LLC bought a new position in Nyxoah during the third quarter valued at about $98,000. Shay Capital LLC bought a new position in shares of Nyxoah during the 2nd quarter valued at approximately $374,000. Finally, Kovack Advisors Inc. grew its holdings in Nyxoah by 148.2% during the second quarter. Kovack Advisors Inc. now owns 57,827 shares of the company’s stock valued at $433,000 after purchasing an additional 34,532 shares during the period.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.